Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EQUIDYNE CORP: IJX (AMEX) -- Ignore unavailable to you. Want to Upgrade?

To: dgrebles who wrote (175)	4/22/2002 2:32:07 PM
From: Skywatcher	Respond to of 179

Equidyne to Participate In CDC-Sponsored Test of Needle-Free Injectors for Vaccinations SAN DIEGO--(BW HealthWire)--April 22, 2002--Equidyne Corp. (AMEX: IJX - news) announced today that it is working with D'Antonio Consultants International Inc. (DCI), a product development company located in Syracuse, N.Y., to conduct a clinical trial of needle-free injection systems pursuant to a Small Business Innovation Research (SBIR) contract DCI was awarded by the Centers for Disease Control and Prevention (CDC). The CDC is seeking to develop safe, high-speed vaccination devices which are suitable for mass immunization campaigns, including measles control and eradication efforts. The specific objectives of DCI's contract with the CDC are to design, build, test at the bench, then in animals and finally in humans, a high-speed, needle-free injector device (and associated accessories) for mass immunization campaigns which could use conventional, off-the-shelf formulations of vaccines, such as measles (MEA) or measles-mumps-rubella (MMR) combination vaccines. ``The disposable INJEX ampule is very similar to the one we have developed for our high speed injector, and has the advantage of already being in production,'' said Linda D'Antonio, vice-president of marketing for DCI and co-investigator on the project. ``We are pleased Equidyne has agreed to participate in this trial so we can learn more about their ampule performance and explore avenues for possible future cooperation.'' In testing being conducted at the State University of New York (SUNY) Upstate Medical University in Syracuse, N.Y., DCI will inject experimental animals to assess dose penetration and dispersion. Followup studies will determine how DCI's high-speed injectors compare to conventional needles and syringes in administering vaccine. No U.S.-licensed, high-speed vaccination devices of unquestioned safety are currently available, because of concern for traditional ``jet guns'' which vaccinate consecutive patients from the same nozzle, according to Bruce G. Weniger, MD, assistant chief for Vaccine Development at CDC's National Immunization Program, which oversees the contract with DCI. ``We welcome this collaboration between Equidyne and DCI to research and develop new high-workload jet injectors using disposable-cartridge technology that avoids reuse of components having contact with the patient,'' said Dr. Weniger. The CDC contract specifies the new device should be high-speed by delivering 1 injection every 6 seconds and thus allowing for the rapid vaccination by limited manpower of many individuals in a short period of time. The device should also demonstrate vaccine efficacy and a tolerable safety profile in terms of pain, local tissue reactions, and other adverse effects, and should produce no ``sharps'' waste requiring special handling for safe disposal. ``We are pleased to be working together with the CDC, DCI and the staff at SUNY Upstate Medical University in this important clinical study,'' commented Dr. James Gavin III, chairman of Equidyne Corp. ``This study may not only assist in efforts to control measles and other childhood diseases, but may also point the way for better methods to deliver other vaccinations and medications for anthrax, smallpox and plague in the event of bio-terrorism.'' CC

To: dgrebles who wrote (175)	8/19/2002 3:01:20 PM
From: Skywatcher	Respond to of 179

We've been duped by management or they were duped by the ROSCH spy! OBVIOUSLY the guy they brought in from ROSCH as a consultant is the INSIDE GUY.....2 weeks after he's announced....THEY TRY AND BUY THE COMPANY FOR NOTHING! Check it out....the guy is a shill.... Equidyne Corp. (AMEX:IJX - News) announced today that it has engaged Peter Frey, the former Director of Research and Development for Rosch AG Medizintechnik, a needle-free technology company based in Germany, as a consultant. Frey previously served Rosch AG as its principal representative for establishing strategic relationships with pharmaceutical companies, a role which will continue to be his principal focus at Equidyne. Frey's professional background includes extensive work in key positions for major pharmaceutical corporations including Pharmacia, Genentech, Serono, and Sanofi. NINETY CENTS IS THE CASH VALUE.....other words they are trying to buy it FOR FREE! CC

To: dgrebles who wrote (175)	9/3/2002 12:05:43 PM
From: Skywatcher	Respond to of 179

This news is unbelievable....and WHY IJX isn't STEPPING IN NOW!?!?!?!? Reuters Company News Weston Medical dives 90 pct on product blow Tuesday September 3, 6:41 am ET By Ben Hirschler, European Pharmaceuticals Correspondent (Wraps CEO interview, analyst comment, latest shares) LONDON, Sept 3 (Reuters) - Weston Medical Group Plc shares lost 90 percent of their value on Tuesday as the British needle-free injection specialist delayed the launch of a key product and said it would need additional funding. The flagship Intraject device will not now be launched until at least mid-2005 while the firm makes design modifications, after tests showed some products were not working properly. "It's a bombshell. There was no warning of this and it's very late in the day to start saying there are problems," said Robin Campbell, industry analyst at WestLB Panmure. Shares in the group, which floated in May 2000 and peaked at 275 pence in January 2001, traded down to as little as four pence after closing on Monday at 50. They were quoted off 87 percent at 6-1/2 by 1040 GMT. Weston Medical has trumpeted its Intraject device as a less painful and more effective way of delivering drugs into the body, winning backing from major drug firms including Roche Holding AG (ROCZg.VX), GlaxoSmithKline Plc (London:GSK.L - News) and Abbott Laboratories Inc (NYSE:ABT - News). Investors had expected some of these licensee partners to start filling the device with their medicines in 2003. That will not now happen, leaving the firm with a yawning funding gap. Chief Executive Christopher Samler said it was not possible yet to say how much new cash was needed. "It all depends on the extent of the delay and we haven't fully bottomed that out," he told Reuters. All options for fund-raising were being considered, he added. "There are all sorts of ways of cutting this, from a rights issue, to a restructuring of our agreements (with pharmaceutical companies), through to potential M&A considerations." Weston Medical had cash reserves of 21 million pounds ($32.60 million) at the end of March and has been burning its way through just under one million pounds a month, excluding capital expenditure. The group discovered that some of its devices were not working properly after conducting new in-house tests about a month ago. "The results surprised us hugely. Some of the devices weren't performing as expected, they weren't as consistent as expected," Samler said. The company is now examining three components for possible modification -- the capsule and size of opening, the shock absorber and the gas pressures used. CC